Physician profile
Michael T Cecil
NPI 1295737955
$1,720.47
in general payments reported to CMS, 2019-2025
14 companies · $686 in 2025
The $686 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $65.74 · 2021: $17.42 · 2022: $81.10 · 2023: $417 · 2024: $289 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.65 |
| Education | $231.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $494.96 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $316.62 | 2022-2025 | Nucala |
| Genzyme Corporation | $265.14 | 2019-2025 | |
| Optinose US, INC. | $220.21 | 2019-2025 | |
| Medtronic, INC. | $165.27 | 2025 | Propel, Ligasure |
| Stryker Corporation | $60.74 | 2019-2025 | Scopis Ent |
| Amgen INC. | $48.51 | 2025 | Tezspire |
| Smith+Nephew, INC. | $38.78 | 2024 | |
| Mallinckrodt Enterprises LLC | $26.78 | 2019 | |
| Integra Lifesciences Corporation | $24.01 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Merck Sharp & Dohme LLC | $17.32 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.07 | 2020 | |
| Medtronic USA, INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.